Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 713M 623M 573M 534M 1.01B 67.87B 1.03B 6.87B 2.67B 33.36B 2.68B 2.62B 115B P/E 2026 *
3.67x
P/E 2027 * 3.51x
Enterprise Value 713M 623M 573M 534M 1.01B 67.87B 1.03B 6.87B 2.67B 33.36B 2.68B 2.62B 115B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.49x
Free-Float
96.84%
Yield 2026 *
-
Yield 2027 * -
1 day+5.10%
1 week+4.84%
Current month+2.85%
1 month+33.64%
3 months+22.32%
6 months+1.41%
Current year+28.49%
1 week 3.99
Extreme 3.99
4.39
1 month 3.14
Extreme 3.145
4.39
Current year 2.95
Extreme 2.95
5.78
1 year 0.67
Extreme 0.6701
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 01/04/2024
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Chairman

85,052 0.0517%
06-16Free

Director

63,481 0.0386%
06-16Free

Director

63,481 0.0386%
Change 5-day change 1-year change 3-year change Capi.($)
+5.10%+4.84%+465.27%-58.33% 713M
+3.34%+0.70%+60.09%+13.32% 320B
-1.25%0.00%+31.51%-2.02% 72.44B
+3.17%+5.99%+47.13%+115.43% 9.42B
+1.24%+4.51%+6.84%-0.78% 8.65B
-0.46%+3.98%-8.00%+4.61% 4.41B
+8.48%+25.95%+23.98%+52.99% 4.52B
+0.43%+6.02%-36.00%+22.59% 3.43B
+1.35%+2.58%+50.25%+60.70% 2.79B
-1.28%+7.61%+15.42%-23.44% 2.19B
Average +2.01%+3.81%+65.65%+18.51% 42.85B
Weighted average by Cap. +2.48%+0.94%+52.43%+13.09%

Financials

2026 *2027 *
Net sales 459M 402M 369M 344M 653M 43.75B 663M 4.43B 1.72B 21.5B 1.72B 1.69B 74.1B 478M 418M 384M 358M 679M 45.55B 690M 4.61B 1.79B 22.39B 1.8B 1.76B 77.15B
Net income 188M 165M 151M 141M 267M 17.92B 271M 1.82B 706M 8.81B 707M 691M 30.36B 210M 183M 169M 157M 298M 19.98B 303M 2.02B 787M 9.82B 788M 771M 33.85B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
02/07/26 $4.330 +5.10% 2,651,198
01/07/26 $4.120 -2.14% 1,653,028
30/06/26 $4.210 -2.09% 2,586,091
29/06/26 $4.300 +4.12% 3,501,858
26/06/26 $4.130 +7.55% 7,108,527
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.330USD
Average target price
6.100USD
Spread / Average Target
+40.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock